Latest common stock for PARD: $1.2M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
Poniard Pharmaceuticals (PARD) currently reports a common stock of $1.2M as of September 2011. That compares with $970K in the prior-year period — up 24.1% year over year. Use the charts on this page to explore Poniard Pharmaceuticals's common stock history and peer comparisons.
Poniard Pharmaceuticals's common stock increased from $970K to $1.2M — a 24.1% year-over-year increase (period ending September 2011). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Poniard Pharmaceuticals reported $1.2M in common stock as of September 2011. That compares with $970K in the prior-year period — up 24.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current common stock of $1.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Poniard Pharmaceuticals, and consider following PARD for alerts when major investors trade the stock.
Poniard Pharmaceuticals is classified in the Healthcare sector. On common stock, it currently shows $1.2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PARD with unrelated industries.